Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241914440 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Věra Malinová und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Pra…. Hauptthemen laut MEDLINE: Gaucher Disease. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Ministry of Health of the Czech Republic.
Abstract (Originalsprache)
A personalized treatment decision for Gaucher disease (GD) patients should be based on relevant markers that are specific to GD, play a direct role in GD pathophysiology, exhibit low genetic variation, reflect the therapy, and can be used for all patients. Thirty-four GD patients treated with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) were analyzed for platelet count, chitotriosidase, and tartrate-resistant acid phosphatase activity in plasma samples, and quantitative measurement of Lyso-Gb1 was performed in dried blood spots. In our ERT and SRT study cohorts, plasma lyso-GL1 correlated significantly with chito-triosidase (ERT: r = 0.55, p < 0.001; SRT: r = 0.83, p < 0.001) and TRAP (ERT: r = 0.34, p < 0.001; SRT: r = 0.88, p < 0.001), irrespective of treatment method. A platelet count increase was associated with a Lyso-Gb1 decrease in both treatment groups (ERT: p = 0.021; SRT: p = 0.028). The association of Lyso-Gb1 with evaluated markers was stronger in the SRT cohort. Our results indicate that ERT and SRT in combination or in a switch manner could offer the potential of individual drug effectiveness for particular GD symptoms. Combination of the key biomarker of GD, Lyso-Gb1, with other biomarkers can offer improved response assessment to long-term therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- ARCHIMEDlife Laboratories, 1110 Vienna, Austria.
ORCID-Profile: Lenka Murgašová, Martin Magner
Förderung
- Ministry of Health
- Ministry of Health of the Czech Republic
Zitieren
APA
Malinová, V., Poupětová, H., Řeboun, M., Dvořáková, L., Reichmannová, S., Švandová, I., Murgašová, L., Kasper, D. C., & Magner, M. (2023). Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914440
Vancouver
Malinová V, Poupětová H, Řeboun M, Dvořáková L, Reichmannová S, Švandová I, et al. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914440
BibTeX
@article{Malinov2023,
author = {Malinová, Věra and Poupětová, Helena and Řeboun, Martin and Dvořáková, Lenka and Reichmannová, Stella and Švandová, Ivana and Murgašová, Lenka and Kasper, David C and Magner, Martin},
title = {Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241914440}
}
EUVIMED